Braveheart Bio, Inc. Common Stock (BRVE) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $1.58B. Nama's AI scorecard rates it Hold, 4.3 out of 10.
AI scorecard
Hold · 4.3/10
The sections balance. As of Nov 20, 2026.
Shariah screen
Can't Tell
A figure the screen needs is missing, so it can't tell.
Off its high
-36.3%
How far the last close sits under the highest price of the past five years.
Market cap
$1.58B
Trailing P/E
—
Price / book
3.5
Price / sales
—
FCF yield
—
Dividend yield
—
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Revenue growth (YoY)
—
Revenue growth (3-yr annual)
—
EPS growth (YoY)
—
FCF/share growth (YoY)
—
Beta
—
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
BRVE earnings
Next report: Mar 18, 2027 (Q4 2026, EPS estimate -$0.27).
Beat the EPS estimate in 1 of 2 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q3 2026
Nov 10, 2026
-$0.51
-$0.60
+15.0%
$0
Q2 2026
Sep 8, 2026
-$2.51
$2.69
-193.3%
$0
BRVE analyst price target
Median target $46.50 from 4 analysts, ranging $40.00 – $49.00.
Nama's AI scorecard currently rates Braveheart Bio, Inc. Common Stock Hold (4.3 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does BRVE report earnings?
Braveheart Bio, Inc. Common Stock's next scheduled report is on Mar 18, 2027. Analysts expect EPS of -$0.27.
What is the BRVE price target?
The median analyst price target from 4 analysts is $46.50, with a range of $40.00 – $49.00.
Is BRVE Shariah compliant?
Nama's AAOIFI-style screen reads Braveheart Bio, Inc. Common Stock as Can't Tell. A figure the screen needs is missing, so it can't tell.